Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

In this installment, we delve into one of the most debated scientific advancements of our time: CRISPR gene-editing ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

Colossal Biosciences wants to bring back the woolly mammoth and has raised $200 million at a $10.2 billion valuation to do it ...

CRISPR gene-editing technology presents a possible solution for feeding a growing population, but incorporating CRISPR into ...

CRISPR Therapeutics is a mid-stage biotech ... Investor enthusiasm about technology and growth stocks, and the economic environment ahead, drove the momentum. After all, the artificial ...

The scientific team at the laboratory is headed by a group of women with a track record in genomic science, molecular ...

ErlySign’s innovation is a biomarker-based test kit capable of detecting oral precancerous conditions within just 15 minutes ...

Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics ...